Theriva Biologics Secures Funding for Innovative Cell Projects
Theriva Biologics Secures Funding to Advance Innovative Therapies
Theriva™ Biologics (NYSE American: TOVX), a pioneering clinical-stage company dedicated to innovative cancer therapeutics, has recently made headlines by winning grant funding from the National Knowledge Transfer Program of the Spanish government. This funding, totaling €2.28 million, is intended to spearhead a significant project in collaboration with Universitat Autònoma de Barcelona (UAB) aimed at enhancing Theriva's ground-breaking suspension cell platform used for manufacturing adenovirus and adeno-associated virus (AAV) therapies.
Details of the Funding Award
As part of the award, Theriva will receive a loan of €1.33 million, set to be disbursed as a lump sum in the fourth quarter, followed by a seven-year repayment period starting three years after the award date. In addition, UAB will benefit from a grant of €0.95 million, allocated in annual installments over the upcoming three years to further support the project.
The THERICEL Project: A Focus on Efficiency
The THERICEL project is designed to explore the feasibility of using Theriva's proprietary A549 suspension cell platform specifically for the clinical manufacture of adenoviral and AAV therapies. This innovative approach is expected to significantly boost manufacturing efficiency while lowering costs compared to traditional adherent cell platforms. Theriva plans to utilize this funding effectively to scale up the production of VCN-01, its leading oncolytic virus candidate presently in Phase 2b clinical trials for treating advanced pancreatic ductal adenocarcinoma (PDAC). Furthermore, researchers at UAB will assess the feasibility of this suspension cell line in producing AAV products for gene therapy applications.
Comments from Theriva's Leadership
Steven A. Shallcross, CEO of Theriva Biologics, expressed enthusiasm regarding the funding award, noting how it not only provides substantial financial support but also reinforces the credibility of their therapeutic strategy. “This funding will expedite the initiation of our innovative suspension cell platform, enhancing our position at the forefront of oncolytic virus development,” Shallcross stated. He also emphasized the significance of collaboration with UAB in striving to meet the pressing medical needs of patients.
About Theriva Biologics
Theriva™ Biologics is focused on developing therapeutic solutions for cancer and related diseases, addressing high unmet medical needs. Their unique oncolytic adenovirus platform is engineered for multiple methods of delivery, such as intravenous and intravitreal applications, with the goal of inducing tumor cell death and facilitating deeper penetration of co-administered cancer therapies. The company's primary candidates include VCN-01, designed to selectively target and destroy tumor cells, as well as SYN-004 and SYN-020, which aim to mitigate adverse effects from treatments and improve local gastrointestinal health.
Frequently Asked Questions
What is the significance of the THERICEL project?
The THERICEL project aims to improve the efficiency and cost of manufacturing viral therapies, potentially revolutionizing production methods in the biopharmaceutical industry.
How will the funding be used?
The funding will support scaling up Theriva’s innovative suspension cell platform to enhance the clinical manufacture of adenoviral and AAV therapies.
Who is collaborating with Theriva on this project?
Theriva is collaborating with the Universitat Autònoma de Barcelona (UAB) to further develop the suspension cell platform and conduct related research.
What are the key products in Theriva's pipeline?
Key products include VCN-01, an oncolytic adenovirus; SYN-004, designed to protect the microbiome; and SYN-020, aimed at treating gastrointestinal disorders.
When can we expect updates on the THERICEL project?
Updates will likely be shared as Theriva progresses with the project and initiates the scaling-up process, especially after the funding is allocated.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Ease Capital Introduces Innovative Fixed-Rate Financing Option
- Exploring Talkroute: The Ideal Virtual Phone Solution for Business
- Haig Partners Facilitates Major Deal for Bulldog Kia's Sale
- Securities Class Action Filed for Allarity Therapeutics (ALLR) Investors
- How GPARENCY’s Innovative Brokerage Model is Transforming Real Estate
- Viatris Set to Share Q3 2024 Performance Insights Soon
- Precigen Focuses on Innovative Therapies at Upcoming Healthcare Event
- Graphite One Plans to Extend Warrant Expiry Date for Investors
- PAVmed Strengthens Position for Nasdaq Compliance Reinstatement
- Innovative Immunotherapy Institute Launches to Combat Cancer
Recent Articles
- Provident Bank Grants $88K to Support Local Non-Profits' Missions
- Siyaa Munjal Honored with Women in Supply Chain Award
- InterDigital Sets Ambitious $1 Billion Revenue Goal for 2030
- Soluna Holdings Unveils Project Rosa: A New Era in Renewable Computing
- FactSet's Investor Day 2024: A Look Ahead for Investors
- BioVie Receives Key Approval for Long COVID Treatment Trial
- CrowdStrike Launches New Accelerator to Boost Cybersecurity Startups
- CAPREIT Reveals Monthly Distribution for Investors
- Unlocking the Future of Auditing with CCH Axcess Audit Solutions
- DO Apparel Elevates Custom Sportswear Production Strategy
- LeaseLock Welcomes John Lis as New Sales SVP to Drive Growth
- Tree Island Steel Declares New Quarterly Dividend for Shareholders
- Gibson Energy Refreshes Share Repurchase Strategy to Benefit Investors
- MidOcean Energy Expands Presence in LNG Market with New Deal
- September 2024 Distribution Announcement by ERES REIT
- Moderne Ventures Surpasses $230 Million in Latest Funding Round
- Celldex Therapeutics to Present Phase 2 Study Findings at EADV
- Exploring NC410 and Pembrolizumab in Promising Cancer Trials
- Capella Space Secures $15 Million Contract for SAR Technology
- CAPREIT Declares Competitive Monthly Distribution for September
- RAFTR Roofing + Exteriors Joins Forces with RoofMarketplace Inc.
- Outlook Therapeutics Prepares for Upcoming Investor Interaction
- Innovative Solutions Against Unauthorized Broadband Sharing
- Salesforce Invests $23 Million in Education for AI Skills
- Inotiv, Inc. Enhances Credit Agreement and Boosts Liquidity
- Ryan Specialty Strengthens Portfolio with Ethos Acquisition
- Provident Bank Supports Local Non-Profits with $88,000 in Grants
- Rain Partners with Workday for Enhanced Financial Solutions
- Recent Data on Elraglusib Combats Pancreatic Cancer Treatment Challenges
- FactSet's 2024 Investor Day Promises Exciting Insights
- The Power of Emotional Intelligence in Project Management Today
- Over $170 Million Boost for Solar Energy with Monarch and Invenergy
- Chase Freedom® Offers Exciting Q4 2024 Categories for Cashback
- Vera Therapeutics Enhances R&D Efforts for Atacicept
- goTenna Secures $15 Million Contract for Innovative Air Force Solutions
- Innovative Startups Transforming Industries in 2024 Cohort
- Odyssey Transfer and Trust Welcomes Bill Collins as CRO for Growth
- 3iQ Partners with CoinDesk Indices to Enhance Digital Asset Investment
- Football Fans Love Guacamole: A Delicious Game Day Tradition
- Exploring the Future of Non-Invasive Prostate Treatments
- HiringBranch Joins AWS Partner Network to Enhance Hiring Solutions
- Exciting Developments in GV20 Therapeutics' Novel Therapies
- goTenna Secures $15M Contract for Enhanced Air Force Solutions
- Firstrust Bank Secures $1 Billion Facility to Elevate College Ave
- European REIT ERES Confirms Monthly Distribution for September
- Transforming Air Quality Solutions for Biotech Industries
- Celldex Therapeutics Shares Exciting Study Results in CSU Treatment
- CSA Medical Showcases Innovations in Bronchitis Treatment
- Exciting Developments from Outlook Therapeutics: Upcoming Events
- Hästens and Maria Sharapova Unite to Champion Sleep Excellence